Immediate Impact
62 standout
Citing Papers
Present and future of cancer nano-immunotherapy: opportunities, obstacles and challenges
2025 Standout
Flavonoids: Antioxidant Powerhouses and Their Role in Nanomedicine
2024 Standout
Works of Julie C. Smith being referenced
Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer—A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib
2018
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Julie C. Smith | 30 | 53 | 32 | 33 | 17 | 170 | |
| P André | 15 | 27 | 22 | 19 | 24 | 287 | |
| Yen-Ling Huang | 18 | 60 | 48 | 40 | 19 | 294 | |
| Adrian YS Yip | 33 | 101 | 6 | 25 | 20 | 267 | |
| Huda Asif | 55 | 59 | 8 | 29 | 16 | 273 | |
| Motoki Takenaka | 34 | 37 | 14 | 18 | 27 | 272 | |
| Adhari AlZaabi | 16 | 34 | 31 | 16 | 17 | 272 | |
| Fatema Tuz Zohora | 12 | 44 | 6 | 14 | 14 | 274 | |
| Gizem Alkurt | 14 | 70 | 17 | 18 | 12 | 277 | |
| Richard Corlin | 56 | 35 | 31 | 9 | 14 | 266 | |
| Antony Raharja | 6 | 38 | 17 | 27 | 16 | 279 |
All Works
Loading papers...